Home > Back to Publisher > Report Information

Sleeper Diseases: Forecast and Assessment of Neglected Disease Market Opportunities

CHI Insight Pharma Reports
February 1, 2006
SKU: CHI1219457

Abstract Table of Contents Related Reports

Sleeper diseases comprise a broad spectrum of increasingly recognized conditions with various degrees of neuropsychiatric involvement. Many of these conditions are now clearly defined, earning them increasing acceptance as real disorders that can and should be addressed by pharmacotherapy.

Several of these emerging sleeper diseases share key properties that make them highly interesting for the pharmaceutical industry:

They are well defined and “real” beyond any reasonable doubt, although their etiology might be unknown or scientists’ understanding of them might be highly incomplete.
They affect a considerable number of otherwise healthy individuals in ways that significantly compromise their quality of life, social functioning, and professional accomplishments.
They respond to treatment with currently available medications (or at least some of their constituent aspects do to a limited degree), and novel drugs (frequently based on genetic insights that reveal possible targets) are being investigated on the basis of scientifically defendable working hypotheses.

In this report, five syndromes the author believes will develop into significant pharmaceutical markets through 2015 have been evaluated:

Autism: A Developmental Disorder That Is Massively on the Rise
Compulsions, Phobias, Panic Attacks: Disruptive Intrusions of Normal Life
Chronic Fatigue Syndrome and Fibromyalgia: Enigmatic Etiological Models
Eating Disorders: Beyond the Obesity Debate
Restless Legs Syndrome: Much More Than a Nuisance

Autism: A Developmental Disorder That Is Massively on the Rise: Symptoms, Diagnosis, and Epidemiology; Etiology; Inconclusive Results of Genetic Investigations; Current Drug Treatments and Trials Involving Drugs Approved for Other Indications; Potential New Drugs for Autism and Autistic Spectrum Disorders; The Autism Drug Therapy Market to 2015; References; Index; Figures and Tables; Figure 1. Key Symptoms of Autism; Figure 2. Incidence of U.S. Autism Cases, 1992 to 2003; Table 1. Drugs Approved for Other Indications That Are Used to Manage or Are in Clinical Trials for Autism; Table 2. Potential New Drugs for Use in Autism
Compulsions, Phobias, Panic Attacks: Disruptive Intrusions of Normal Life: Obsessive-Compulsive Disorder; Panic Disorder and Phobias; Current Drug Treatments for OCD, APD, and Social Phobia; Other Drug Therapies and Developments Based on Available Drugs; Drug Candidates in Development; Market Scenarios for OCD, APD, and Social Phobia; New Mechanisms Are Needed to Compete with Psychotherapy; A Market Waiting for One More Boost; References; Index; Figures and Tables; Figure 1. Disturbed Neurotransmitter Pathways in OCD; Figure 2. Projected Combined Market for OCD, APD, and SAD, to 2015; Table 1. Symptoms of OCDs, Panic Attacks, and Phobias; Table 2. SSRIs Currently Used in Treatment of OCD, APD, and SAD; Table 3. Drug Candidates in Development for OCD and Panic Disorders
Chronic Fatigue Syndrome and Fibromyalgia: Enigmatic Etiological Models: Chronic Fatigue Syndrome and Fibromyalgia Syndrome: Diagnostic Criteria; The Enigma of Etiology; Epidemiology and Economic Implications of Chronic Fatigue Syndrome and Fibromyalgia Syndrome; Currently Available Drugs under Development for Fibromyalgia Syndrome as Additional Indication; Pharmacotherapeutic Concepts for the Future; Scenarios for the Chronic Fatigue Syndrome and Fibromyalgia Drug Market to 2015; References; Index; Figures and Tables; Figure 1. Location of the “Tender Points” in Fibromyalgia; Figure 2. Projected Growth in Drug Sales for FMS and CFS, to 2015; Table 1. Signs and Symptoms Associated with FMS; Table 2. Marketed Drugs under Study for Label Extension to FMS; Table 3. Pharmacotherapies under Investigation for FMS and CFS
Eating Disorders: Beyond the Obesity Debate: Introduction; Assessment Tools for Eating Disorders; Epidemiology and Psychiatric Comorbidity; Etiology of the Eating Disorders; Current Pharmacotherapeutic Approaches; New Pharmacologic Approaches to Eating Disorders; Scenarios for the Developing Eating Disorder Pharmacotherapy Market; References; Index; Figures and Tables; Figure 1. Synergizing Risk Factors for the Development of Eating Disorders; Figure 2. Schematic Representation of Neuropeptide Circuitries Involved in Appetite Control and Eating Disorders; Figure 3. Projected Market Size in U.S. Millions of Dollars, to 2015; Table 1. Most Frequently Used Assessment Tools for Eating Disorders; Table 2. Medications Currently Used in Treatment of Eating Disorders; Table 3. Experimental Approaches to the Pharmacotherapy of Eating Disorders; Table 4. Estimated Number of U.S. Individuals Meeting Criteria for Eating Disorders and Corresponding Market Size, 2005 to 2015
Restless Legs Syndrome: Much More Than a Nuisance: Symptoms and Sequels; Prevalence and Assessment of Severity; Causes; Current and Potential Future Pharmacotherapies; Projections for the RLS Market to 2015; The Treatment Population and Its Projected Development; Estimation of the Sales Volume Potential; A Scenario for the RLS Drug Market in 2015; References; Index; Figures and Tables; Figure 1. Possible Pathophysiologic Basis of Restless Legs Syndrome (RLS) and Periodic Limb Movements (PLM); Figure 2. Recommended Treatment Algorithm for Intermittent, Daily, and Refractory RLS; Figure 3. RLS-Related Drug Sales (Estimates); Table 1. Summary of Recently Published Cross-Sectional, Population-Based Restless Legs Syndrome/Periodic Limb Movement Disorder Epidemiologic Studies; Table 2. Drugs in Development for RLS Indications; Table 3. Estimated Number of U.S. Individuals with Moderate or Severe RLS as Opposed to the Diagnosed Population, 2005 to 2015; Table 4. Estimated Number of Individuals in the United Kingdom, Germany, France, Spain, and Italy with Moderate or Severe RLS as Opposed to the Diagnosed Population, 2005 to 2015

Sleeper Diseases: Forecast and Assessment of Neglected Disease Market Opportunities

Share this report

Other tasks

Research Assistance

Related Markets

Behavioral Health Reports

Free Alert Me service